EM2307D "Should all Patients with Chronic Kidney Disease be Treated with a Sodium-Glucose Transporter-2 Inhibitor?" (IM GR-072823)

Purpose and Overview

The purpose of this presentation is to teach the broad internal medicine community about the benefits and risks of SGLT2 inhibitors in patients with chronic kidney disease with or without diabetes.  This class of agents have been shown to improve kidney and cardiovascular outcomes in CKD patients as well as those with heart failure with or without chronic kidney disease.  The effects of these drugs go far beyond any glycemic effects and their clinical outcome benefits are independent of glucose lowering. The physiology, pharmacology and extra glycemic effects of SGLT2 inhibitors, large-scale outcomes trials, clinical practice guidelines and clinical practice applications of these drugs will be discussed.  All IM participants will benefit from the new and emerging knowledge highlighted in this presentation. 

Target Audience

UT Southwestern faculty, fellows, residents and medical students, community physicians, nurse clinicians, physician assistants and nurses.

Learning Objectives

At the conclusion of this activity, the participant should be able to:

  • Readily explain the physiology of kidney glucose metabolism and the site and mechanism of action of SGLT2 inhibitors on the kidney.
  • Appreciate the efficacy and safety of SGLT2 inhibitors in patients with chronic kidney disease with or without diabetes.
  • Identify which patients with chronic kidney disease are candidates for prescribing SGLT2 inhibitors.
Course summary
Available credit: 
  • 1.00 AMA
Course opens: 
Course expires: 

Photo: First Last, M.D.Robert Toto, M.D.
Professor of Internal Medicine, Division of Nephrology
Associate Dean, Translational Science

Available Credit

  • 1.00 AMA


Please login or create an account to take this course.

Required Hardware/software

Activities should be run with recent versions of common browsers, including Internet Explorer, Firefox and Google Chrome